Marshall Wace
NXTC icon

Marshall Wace’s NextCure NXTC Stock Holding History

Marshall Wace’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,292
Closed -$160K – 3545
2025
Q4 		$160K Buy
+11,292
New +$117K ﹤0.01% 2638
2022
Q1 		– Sell
-1,166
Closed -$84K – 3808
2021
Q4 		$84K Sell
1,166
-7,422
-86% -$621K ﹤0.01% 3423
2021
Q3 		$695K Sell
8,588
-757
-8% -$66.4K ﹤0.01% 2229
2021
Q2 		$900K Buy
9,345
+5,215
+126% +$534K ﹤0.01% 1872
2021
Q1 		$496K Sell
4,130
-431
-9% -$62.4K ﹤0.01% 1946
2020
Q4 		$596K Sell
4,561
-4,131
-48% -$534K ﹤0.01% 1397
2020
Q3 		$918K Buy
8,692
+6,200
+249% +$762K 0.01% 1055
2020
Q2 		$641K Buy
2,492
+1,898
+320% +$723K ﹤0.01% 1125
2020
Q1 		$264K Buy
+594
New +$317K ﹤0.01% 1121

Other funds holding NXTC

SCM
Squadron Capital Management Westmont, Illinois $273M AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Marshall Wace's NXTC Position: Q1 2026 in Review

Marshall Wace sold out of NextCure (NXTC) in Q1 2026, closing a stake of 11,292 shares — an estimated $160K sold.

Marshall Wace first reported a position in NXTC in Q1 2020 and held it in 9 quarters. The position peaked at $918K in Q3 2020. 26 funds tracked by Wall St. Rank hold NXTC as of Q1 2026.

  • Marshall Wace reported no remaining NextCure position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 11,292 NextCure shares in Q1 2026, an estimated $160K.
  • Marshall Wace first reported a position in NextCure in Q1 2020 and held it in 9 quarters.
  • Marshall Wace's NextCure position peaked at $918K in Q3 2020.
  • 26 funds tracked by Wall St. Rank held NextCure as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.